Literature DB >> 33168348

HPV cervical infections and serological status in vaccinated and unvaccinated women.

Carmen Lía Murall1, Bastien Reyné1, Christian Selinger1, Claire Bernat1, Vanina Boué1, Sophie Grasset1, Soraya Groc1, Massilva Rahmoun1, Noemi Bender2, Marine Bonneau3, Vincent Foulongne4, Christelle Graf3, Eric Picot5, Marie-Christine Picot6, Vincent Tribout5, Tim Waterboer2, Ignacio G Bravo1, Jacques Reynes7, Michel Segondy4, Nathalie Boulle4, Samuel Alizon8.   

Abstract

Understanding genital infections by Human papillomaviruses (HPVs) remains a major public health issue, especially in countries where vaccine uptake is low. We investigate HPV prevalence and antibody status in 150 women (ages 18 to 25) in Montpellier, France. At inclusion and one month later, cervical swabs, blood samples and questionnaires (for demographics and behavioural variables) were collected. Oncogenic, non-vaccine genotypes HPV51, HPV66, HPV53, and HPV52 were the most frequently detected viral genotypes overall. Vaccination status, which was well-balanced in the cohort, showed the strongest (protective) effect against HPV infections, with an associated odds ratio for alphapapillomavirus detection of 0.45 (95% confidence interval: [0.22;0.58]). We also identified significant effects of age, number of partners, body mass index, and contraception status on HPV detection and on coinfections. Type-specific IgG serological status was also largely explained by the vaccination status. IgM seropositivity was best explained by HPV detection at inclusion only. Finally, we identify a strong significant effect of vaccination on genotype prevalence, with a striking under-representation of HPV51 in vaccinated women. Variations in HPV prevalence correlate with key demographic and behavioural variables. The cross-protective effect of the vaccine against HPV51 merits further investigation.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute infections; Cross-protection; Genital infections; HPV; Serology; Vaccination

Mesh:

Substances:

Year:  2020        PMID: 33168348     DOI: 10.1016/j.vaccine.2020.10.078

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Cytokine response following perturbation of the cervicovaginal milieu during HPV genital infection.

Authors:  Christian Selinger; Massilva Rahmoun; Carmen Lia Murall; Claire Bernat; Vanina Boué; Marine Bonneau; Christelle Graf; Sophie Grasset; Soraya Groc; Jacques Reynes; Christophe Hirtz; Nathalie Jacobs; Samuel Alizon
Journal:  Immunol Res       Date:  2021-04-30       Impact factor: 2.829

2.  Concomitant and productive genital infections by HSV-2 and HPV in two young women: A case report.

Authors:  Ilkay Başak Uysal; Vanina Boué; Carmen Lia Murall; Christelle Graf; Christian Selinger; Christophe Hirtz; Claire Bernat; Jacques Ravel; Jacques Reynes; Marine Bonneau; Massilva Rahmoun; Michel Segondy; Nathalie Boulle; Sophie Grasset; Soraya Groc; Tim Waterboer; Vincent Tribout; Ignacio G Bravo; Sonia Burrel; Vincent Foulongne; Samuel Alizon; Nicolas Tessandier
Journal:  IDCases       Date:  2022-08-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.